Senior Vice President, Chief Medical Officer · REGENXBIO Inc. (RGNX)

Steve Pakola

FY2019 is the first fiscal year CompBrief holds for Steve Pakola as a named executive officer of REGENXBIO; the record below is that year, complete. Every figure below is printed as the company filed it and cited to the filing it came from.

Total disclosed compensation, FY2019

$3,908,793

Salary $305,301Stock awards $0

2nd of 6 named executive officers at Regenxbio by FY2019 total.

6 named officers on file for REGENXBIO, FY2019

Steve Pakola’s pay file — $29

  • 1 fiscal year of pay, line by line
  • 2 equity grants, each cited to its filing
  • RGNX’s disclosed peer group of 15 companies

A PDF and a CSV sent to your email. Every row is cited to its filing.

One-time report. No refunds.

See an example →

Velarion Intel · free for 3 days · no card

See how REGENXBIO’s whole pay program stands against its peers

  • REGENXBIO’s company dashboard and its AI-written, board-ready brief, every figure cited to the filing
  • Peer-group intelligence, custom peer reruns and governance screens
  • Every other company we cover, with alerts when they file
Start my free trial on RGNX→

No card. Nothing is charged, and the trial ends on its own.

Compensation figures as of the proxy filed April 8, 2020 (DEF 14A). Insider transactions since that proxy, current to 2026-11-21.

Free

Get Steve Pakola’s full pay file as a PDF — free

More than this page: up to 10 years of Steve’s pay history, a side-by-side peer comparison, and a one-page board summary — the whole file, yours now and by email.

Steve Pakola compensation by year

REGENXBIO Summary Compensation Table · the one fiscal year held
In US dollars, as REGENXBIO reports it. Most recent year shaded. Totals are the company’s disclosed totals.
ComponentFY2019
Salary$305,301
Bonus$0
Stock awards$0
Option awards$3,460,692
Non-equity incentive$126,700
Pension and deferred compensation$0
All other$16,100
Total$3,908,793

Each year as stated in that year's proxy. A dash means the company reported no figure in that column. Source: REGENXBIO Inc. DEF 14A filed April 8, 2020, accession 0001564590-20-015913, and prior-year filings. Open the filing on EDGAR.

How this page was built: the REGENXBIO Inc. filed document, accession 0001564590-20-015913. Every figure is read from that document and cited to the page and table it appears in. Filed April 8, 2020.

Equity holdings

unvested awards at FY2019 year-end
TypeUnvested unitsValue at year-endExercise price
Option95,000—$54.72

Per the Outstanding Equity Awards at Fiscal Year-End table in REGENXBIO Inc.'s FY2019 proxy; value at the fiscal year-end close, as the company printed it.

Insider transactions since the last proxy

19 Form 4 lines since the FY2019 proxy (filed April 8, 2020)
current to 2026-11-21 · updated nightly
DateTransactionPlanSharesPriceHeld after
2026-11-01Grant or award—34,722$0.00240,263
2026-08-01Tax withholding—7,468$9.69205,541
2026-07-02Exercise or conversion derivative10b5-12,161$0.0064,812
2026-07-02Sale10b5-12,161$13.64213,009
2026-07-02Exercise or conversion10b5-12,161$7.86215,170
2026-07-01Exercise or conversion derivative—36,725$0.0066,973
2026-07-01Sale—36,725$12.86213,009
2026-07-01Exercise or conversion—36,725$7.86249,734

The 8 most recent of 19 lines, each as reported on the Form 4. "10b5-1" marks a trade the filing reports under a pre-arranged trading plan. View every Form 4 filing on EDGAR →

REGENXBIO’s named executive officers, FY2019

as the company reported each
Named executive officerRoleFY2019 total
Kenneth MillsPresident and CEO$6,147,269
Steve Pakola · this pageSenior Vice President, Chief Medical Officer$3,908,793
Vit VasistaSenior Vice President, Chief Financial Officer$2,184,616
Olivier DanosSenior Vice President, Chief Scientific Officer$1,926,420
Patrick ChristmasSenior Vice President, Chief Legal Officer$1,833,033
Curran SimpsonEVP, Chief Operations and Technology Officer$1,825,744

The full REGENXBIO compensation record

free company brief

This page is one person within REGENXBIO's record. The company brief lists every named executive, each linking to their own page.

Compensation, the day it’s disclosed

The CompBrief Daily Digest lists the newest executive and director compensation disclosures as companies file them.

How this record is built

Every figure on this page is one figure from a public SEC filing, printed as the filing states it and cited to the document. Compensation totals are REGENXBIO's own disclosed totals, not summed by Velarion. Insider transactions are read from Form 4 filings and cover every line filed since the most recent proxy. Nothing is estimated by Velarion; where the company does not disclose a value the cell reads "—", and a section appears only where the company discloses the data. Corrections: records@velarion.ai.

Steve Pakola's compensation dossier · One-time report. No refunds.